A

Aveo Pharmaceuticals Inc
F:VPA1

Watchlist Manager
Aveo Pharmaceuticals Inc
F:VPA1
Watchlist
Price: 13.77 EUR -0.4% Market Closed
Market Cap: 478.7m EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

VPA1 Price Targets Summary
Aveo Pharmaceuticals Inc

There are no price targets for VPA1.
VPA1 Lowest Forecast
Wall Street Target
Not Available
VPA1 Average Forecast
Wall Street Target
Not Available
VPA1 Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Aveo Pharmaceuticals Inc Competitors:
Price Targets
1167
Jacobio Pharmaceuticals Group Co Ltd
57% Downside
DBV
DBV Technologies SA
145% Upside
302440
SK Bioscience Co Ltd
22% Downside
002252
Shanghai RAAS Blood Products Co Ltd
7% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
57% Downside
DBV
DBV Technologies SA
145% Upside
302440
SK Bioscience Co Ltd
22% Downside
002252
Shanghai RAAS Blood Products Co Ltd
7% Upside
RCUS
Arcus Biosciences Inc
233% Upside
XGN
Exagen Inc
9% Upside
HPHA
Heidelberg Pharma AG
225% Upside
RYTM
Rhythm Pharmaceuticals Inc
37% Upside

Revenue
Forecast

Revenue Estimate
Aveo Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Aveo Pharmaceuticals Inc's revenue is 55%. The projected CAGR for the next 1 year is 208%.

55%
Past Growth
208%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Aveo Pharmaceuticals Inc

Operating Income forecast
is not available for
Aveo Pharmaceuticals Inc

Net Income
Forecast

Net Income Estimate
Aveo Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
VPA1 intrinsic value, competitors valuation, and company profile.
DCF Valuation
VPA1 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VPA1 stock valuation using valuation multiples.
Wall Street Estimates
VPA1 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VPA1 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VPA1's stock price target?
Not Available

VPA1 doesn't have any price targets made by Wall Street professionals.

What is Aveo Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
208%

For the last 8 years the compound annual growth rate for Aveo Pharmaceuticals Inc's revenue is 55%. The projected CAGR for the next 1 year is 208%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.